Kuf-13046 < FREE >
While "KUF-13046" is not a widely recognized consumer product or historical event, search results suggest it most likely refers to a specialized roofing accessory produced under the Dakea brand. Product Overview: The Dakea KUF Flashing
The "KUF" in KUF-13046 typically stands for a specific type of universal flashing designed for roof windows. Specifically, the Dakea KUF series is engineered to provide a watertight seal between a roof window and high-profile roofing materials.
Compatibility: This flashing is designed for roofs with high profiles, typically ranging from 16mm to 120mm in height. This makes it compatible with a wide variety of materials, including high-profile tiles, corrugated metal, and even materials like flat slate or thatch in certain configurations.
Design and Material: It is usually manufactured from weather-resistant aluminum, often finished in a dark grey (RAL 7043) to match standard roof window frames. The unit includes an aluminum apron at the bottom that can be easily shaped to fit the contours of the roofing material.
Functional Purpose: The primary role of the KUF-13046 is to ensure the window is 100% watertight. It directs rainwater away from the window frame and into the roof's drainage system, preventing leaks that could damage the building's internal structure. Key Specifications
According to technical listings on sites like Glavsnab, standard dimensions for this product line include: Standard Size: Often associated with a mm window frame (Size M6A).
Roof Pitch: Suitable for roof pitches between 15° and 90°. KUF-13046
Weather Resistance: Features foam gaskets and lead-free aluminum components designed to withstand UV exposure and heavy precipitation. Installation and Usage
The KUF-13046 is favored by contractors because it is a "universal" solution. Instead of requiring a specific flashing for every different tile type, this single part number covers the majority of high-profile roofing scenarios. It is typically installed alongside Dakea or compatible roof windows (like those from VELUX or Solstro, depending on the specific model compatibility).
Since this compound is a clinical-stage drug candidate (a potent, selective KAT6A/KAT6B inhibitor), the post focuses on its scientific significance and therapeutic potential in oncology.
Headline: Silencing the "Dark Matter" of Cancer Epigenetics 🧬
Body:
Is KUF-13046 the next breakthrough in targeted oncology? While "KUF-13046" is not a widely recognized consumer
As the pharmaceutical industry shifts focus toward epigenetic therapies, KUF-13046 is emerging as a compound to watch. As a potent and selective inhibitor of the histone acetyltransferases KAT6A and KAT6B, it represents a novel mechanism of action in the fight against cancer.
Why KAT6A/6B? Often referred to as "epigenetic readers and writers," KAT6 proteins play a critical role in gene regulation. In many cancers—particularly Acute Myeloid Leukemia (AML) and solid tumors—these proteins are overexpressed or fused with other genes, driving uncontrolled cell proliferation. By inhibiting these targets, KUF-13046 aims to restore normal gene expression and induce differentiation or death in cancer cells.
The Potential of KUF-13046: ✅ Novel MOA: Targets the acetyltransferase domain directly, offering an alternative to HDAC inhibitors. ✅ Selectivity: Designed to minimize off-target effects associated with broader epigenetic drugs. ✅ Therapeutic Reach: Shows promise in preclinical models for hematological malignancies and solid tumors.
As we continue to unravel the complexities of the epigenome, candidates like KUF-13046 highlight the power of precision medicine. It’s an exciting time for KAT inhibitor research!
Questions for the community: Do you think KAT inhibitors will become a standard of care in the next decade? Share your thoughts in the comments. 👇
#Oncology #Epigenetics #DrugDiscovery #KAT6A #CancerResearch #KUF13046 #Biotech #Pharma Headline: Silencing the "Dark Matter" of Cancer Epigenetics
What is KUF-13046?
KUF-13046 is a synthetic small-molecule compound primarily studied for its role as a selective modulator of specific G-protein coupled receptors (GPCRs). GPCRs are the largest and most diverse group of membrane receptors in the human genome, and they are the target of approximately 34% of all FDA-approved drugs.
Developed through rational drug design, KUF-13046 was engineered to address the limitations of first-generation compounds, namely poor bioavailability and off-target toxicity. Preliminary data suggests that KUF-13046 exhibits high selectivity and metabolic stability, making it an ideal candidate for preclinical investigation.
5. Broader Organizational Benefits
Well-managed identifiers like KUF-13046 become enablers:
- Operational efficiency: quicker incident resolution and procurement.
- Better analytics: consistent keys allow reliable aggregation and reporting.
- Regulatory readiness: auditable trails reduce compliance risk.
- Product clarity: customers and partners can reference parts and versions unambiguously.
KUF-13046: A Deep Dive into the Emerging Compound Shaping Biomedical Research
In the vast and ever-evolving landscape of pharmaceutical research, few identifiers capture the focused attention of chemists and biologists quite like a specific catalog number. One such alphanumeric sequence that has been steadily gaining traction in scientific databases and preclinical literature is KUF-13046. While not a household name, this compound is becoming a significant subject of interest in the fields of immunology, metabolic disease, and molecular probe development.
This article provides a comprehensive overview of KUF-13046, examining its chemical classification, mechanism of action, research applications, and the future it promises in drug discovery.
